From UTI to IC/BPS: How Infection Can Trigger Chronic Bladder Pain

Understanding How Infection Can Lead to a Chronic Bladder Condition

By IC Ally | Reviewed by Clinical Advisors

Many people with interstitial cystitis (IC), also known as bladder pain syndrome (BPS), trace the start of their symptoms back to a urinary tract infection (UTI). The infection is treated—often successfully—with antibiotics, yet the burning, urgency, and bladder pain never fully disappear. This can feel confusing and frustrating. How can symptoms continue when infection tests are negative?

Recent research provides a clear, biological explanation for this post-infectious transition.

Here’s how a single UTI can, in some individuals, trigger a long-term change in the bladder and nervous system.

1. The Initial Infection: How Uropathogenic E. coli Damages the Bladder

Most first-time UTIs are caused by uropathogenic Escherichia coli (UPEC). These bacteria attach to bladder cells using tiny hair-like appendages (fimbriae) and can invade the bladder lining (urothelium). Inside, they form intracellular bacterial communities (IBCs) that resist immune clearance and antibiotics (Robino et al., 2024).

As they replicate, the bladder’s protective barrier becomes inflamed and leaky, allowing potassium and other solutes from urine to irritate deeper tissues and trigger pain and urgency pathways. Research also shows that the nuclear receptor Nur77 plays a protective role in preventing persistent intracellular infection, highlighting how immune dysfunction can contribute to chronic symptoms (Collins et al., 2024).

2. When the Infection Clears but the Inflammation Doesn’t

Antibiotics kill bacteria in the urine but may not reach microbes hiding inside bladder cells. Even after bacteria are eradicated, the immune system and sensory nerves can remain over-activated, maintaining bladder hypersensitivity long after infection resolution. This lingering immune activation, including mast cell involvement, has been observed in both human and animal models of bladder inflammation (Bschleipfer, 2022).

3. Urothelial Repair Failure: The Role of Persistent Barrier Dysfunction

In healthy tissue, the bladder lining (urothelium) repairs itself after injury. However, in some individuals, this healing process fails. Persistent epithelial leakiness allows irritants to reach underlying nerves, sustaining inflammation. Newer findings suggest that signaling molecules such as APF (antiproliferative factor) and altered immune mediators may inhibit proper regeneration, contributing to a chronic, sensitised bladder state (Fu et al., 2024).

4. The Microbiome Disruption: Antibiotics and Dysbiosis

While antibiotics are essential for infection control, they also disturb beneficial bacteria in the vagina, bladder, and gut. Patients with IC/BPS consistently show lower microbial diversity and reduced Lactobacillus levels compared with healthy controls (Fu et al., 2024).

Disruption of the gut–bladder axis further influences inflammation and immune tone. A 2024 Mendelian randomization study demonstrated a causal association between specific gut bacterial species (Bacteroides, Haemophilus, Coprococcus1, Butyricimonas) and IC/BPS risk (Jiang et al., 2024). This supports the concept that the microbiome plays a direct role in bladder health.

5. Central Sensitisation: When the Nervous System Remembers Pain

The bladder and brain communicate continuously through sensory nerves. Repeated inflammation can cause central sensitisation—a process in which pain pathways become hypersensitive, even when the bladder is not inflamed. This means normal sensations, such as bladder filling, are misinterpreted as pain or urgency. Central sensitisation is now recognised as a key component in IC/BPS pathophysiology (Nandwana, 2025).

6. Post-Infectious IC/BPS: The Chronic Phase

Together, these mechanisms create what many researchers now call post-infectious IC/BPS—a chronic, non-infectious bladder pain condition that follows an acute infection.

Common features include:

• Persistent urgency and frequency despite negative urine cultures

• Pain or pressure that worsens as the bladder fills

• Symptom flares triggered by stress, diet, or hormonal changes

The American Urological Association (2022) recognises IC/BPS as a multifactorial syndrome involving urothelial dysfunction, immune dysregulation, and neural hypersensitivity rather than ongoing infection.

7. Managing IC/BPS After Infection

Once infection has been excluded, management focuses on restoring bladder health, calming nerve activity, and rebuilding the microbiome.

Evidence-based strategies include:

• Pelvic-floor physical therapy: targets muscle overactivity that can mimic UTI urgency.

• Oral agents: such as amitriptyline, hydroxyzine, or pentosan polysulfate sodium (PPS) (Hanno et al., 2022).

• Bladder instillations: heparin, lidocaine, or DMSO to soothe and protect the lining.

• Microbiome restoration: using dietary diversity, probiotics, and vaginal Lactobacillus support.

• Lifestyle: stress management, hydration, gentle movement, and tracking triggers to prevent flares.

8. Hope and Healing

IC/BPS is chronic but not hopeless. Many people experience substantial improvement through a personalised, stepwise plan. Understanding the connection between infection, inflammation, and nerve sensitisation empowers patients to focus on healing rather than repeated antibiotics.

References

• American Urological Association. (2022). Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome: AUA Guideline.

• Bschleipfer, T. (2022). Bladder Microbiome in the Context of Urological Disorders. Diagnostics, 12(2), 281.

• Collins, C. A., Waller, C., Batourina, E., et al. (2024). Nur77 protects the bladder urothelium from intracellular bacterial infection. Nature Communications, 15, 8308.

• Fu, C., et al. (2024). The microbiota in patients with interstitial cystitis/bladder pain syndrome: lower urinary microflora diversity and lower Lactobacillus levels. BJU International.

• Hanno, P., et al. (2022). AUA guideline on interstitial cystitis/bladder pain syndrome. Journal of Urology, 208(1), 34–50.

• Jiang, P., Li, C., Su, Z., Chen, D., Li, H., & Chen, J. (2024). Mendelian randomization study reveals causal effects of specific gut microbiota on the risk of interstitial cystitis/bladder pain syndrome. Scientific Reports, 14, 18405.

• Nandwana, D. (2025). Contribution of the Microbiome to Interstitial Cystitis/Bladder Pain Syndrome. Current Opinion in Urology.

• Robino, L., et al. (2024). Presence of intracellular bacterial communities in uroepithelial cells of symptomatic and asymptomatic individuals. BMC Infectious Diseases.

  
  

Disclaimer: This article is for educational purposes only and not a substitute for professional medical advice. If you experience persistent bladder symptoms, consult a qualified clinician for assessment and personalised treatment.